Xi Sun

Shanghai, 200072, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Editor's Note: A Small-Molecule Inhibitor Targeting TRIP13 Suppresses Multiple Myeloma Progression.

Editor's Note: A Small-Molecule Inhibitor Targeting TRIP13 Suppresses Multiple Myeloma Progression.

Journal: Cancer research

Published: June 27, 2025

KAT3B-mediated succinylation of DERL3 suppresses osteogenic differentiation by promoting M1/M2 macrophage polarization.

KAT3B-mediated succinylation of DERL3 suppresses osteogenic differentiation by promoting M1/M2 macrophage polarization.

Journal: Biochemical pharmacology

Published: August 26, 2024

Synergistic effect of nanostructure and calcium ions on improving the bioactivity of titanium implants.

Synergistic effect of nanostructure and calcium ions on improving the bioactivity of titanium implants.

Journal: Royal Society open science

Published: February 23, 2022

A Small-Molecule Inhibitor Targeting TRIP13 Suppresses Multiple Myeloma Progression.

A Small-Molecule Inhibitor Targeting TRIP13 Suppresses Multiple Myeloma Progression.

Journal: Cancer research

Published: December 26, 2018

Targeting the PI3K/Akt/mTOR signaling pathway by pterostilbene attenuates mantle cell lymphoma progression.

Targeting the PI3K/Akt/mTOR signaling pathway by pterostilbene attenuates mantle cell lymphoma progression.

Journal: Acta biochimica et biophysica Sinica

Published: March 25, 2018

Rafoxanide, an organohalogen drug, triggers apoptosis and cell cycle arrest in multiple myeloma by enhancing DNA damage responses and suppressing the p38 MAPK pathway.

Rafoxanide, an organohalogen drug, triggers apoptosis and cell cycle arrest in multiple myeloma by enhancing DNA damage responses and suppressing the p38 MAPK pathway.

Journal: Cancer letters

Published: March 01, 2018

DCZ3301, a novel aryl-guanidino inhibitor, induces cell apoptosis and cell cycle arrest via suppressing the PI3K/AKT pathway in T-cell leukemia/lymphoma.

DCZ3301, a novel aryl-guanidino inhibitor, induces cell apoptosis and cell cycle arrest via suppressing the PI3K/AKT pathway in T-cell leukemia/lymphoma.

Journal: Acta biochimica et biophysica Sinica

Published: December 17, 2017

Dual inhibition of mTORC1/2 by DCZ0358 induces cytotoxicity in multiple myeloma and overcomes the protective effect of the bone marrow microenvironment.

Dual inhibition of mTORC1/2 by DCZ0358 induces cytotoxicity in multiple myeloma and overcomes the protective effect of the bone marrow microenvironment.

Journal: Cancer letters

Published: October 10, 2017

Pterostilbene Induces Cell Apoptosis and Cell Cycle Arrest in T-Cell Leukemia/Lymphoma by Suppressing the ERK1/2 Pathway.

Pterostilbene Induces Cell Apoptosis and Cell Cycle Arrest in T-Cell Leukemia/Lymphoma by Suppressing the ERK1/2 Pathway.

Journal: BioMed research international

Published: February 12, 2017

Dihydrocelastrol inhibits multiple myeloma cell proliferation and promotes apoptosis through ERK1/2 and IL-6/STAT3 pathways in vitro and in vivo.

Dihydrocelastrol inhibits multiple myeloma cell proliferation and promotes apoptosis through ERK1/2 and IL-6/STAT3 pathways in vitro and in vivo.

Journal: Acta biochimica et biophysica Sinica

Published: December 29, 2016

The blueberry component pterostilbene has potent anti-myeloma activity in bortezomib-resistant cells.

The blueberry component pterostilbene has potent anti-myeloma activity in bortezomib-resistant cells.

Journal: Oncology reports

Published: December 13, 2016

Preclinical activity of DCZ3301, a novel aryl-guanidino compound in the therapy of multiple myeloma.

Preclinical activity of DCZ3301, a novel aryl-guanidino compound in the therapy of multiple myeloma.

Journal: Theranostics

Published: November 14, 2016

Showing 1-12 of 15

Last Updated: 09/26/2026